RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ANI Pharmaceuticals Stock

ANI Pharmaceuticals P/S 2024

ANI Pharmaceuticals P/S

1.94

Ticker

ANIP

ISIN

US00182C1036

WKN

A1W15D

As of Sep 30, 2024, ANI Pharmaceuticals's P/S ratio stood at 1.94, a 12.14% change from the 1.73 P/S ratio recorded in the previous year.

The ANI Pharmaceuticals P/S history

ANI Pharmaceuticals Aktienanalyse

What does ANI Pharmaceuticals do?

The company ANI Pharmaceuticals Inc was founded in 2001 and is located in Baudette, Minnesota, USA. ANI Pharmaceuticals is a pharmaceutical company specialized in the development and manufacturing of generic, branded, and biosimilar drugs, as well as novel therapeutic products for a wide range of diseases. ANI Pharmaceuticals has earned a good reputation over the years as a reliable provider of medications for well-known medical conditions. The company specializes in the production of prescription drugs for various conditions, including central nervous system disorders, infectious diseases, cardiovascular diseases, pain, and attention deficit/hyperactivity disorders. ANI Pharmaceuticals' business model is to provide its customers with high-quality, cost-effective, and innovative drugs. The company has an extensive portfolio of products that includes both generics and branded drugs. The company has also specialized in the production of biosimilars - bioproducts that mimic biological drugs whose patent protection has expired. ANI Pharmaceuticals pursues a differentiation strategy to strengthen its competitive position through innovative products, brand building, quality control, and cost leadership. For example, in 2019, the company developed Exservan, a liquid treatment for amyotrophic lateral sclerosis (ALS) that patients can take daily through an enlarged mouth opening. ANI Pharmaceuticals has various business segments: - Generics Business: ANI Pharmaceuticals manufactures a variety of generics for various diseases, including drugs for Parkinson's disease, pain, hypertension, and antidepressants. - Branded Product Business: ANI Pharmaceuticals also markets its own portfolio of branded products, mainly based on critical medical needs. These include Inversine - an oral medication for hypertension, Lithium Carbonate - a medication for mood disorders, and Inderal - a medication for cardiovascular diseases. - Contract Manufacturing Business: ANI Pharmaceuticals also offers contract manufacturing services for other pharmaceutical companies. ANI Pharmaceuticals provides a range of development and manufacturing services, including process development, formulation development, scale-up, validation, packaging, and distribution. - Biosimilars Business: ANI Pharmaceuticals specializes in the production of biosimilars and is working on the development of biological replicas of drugs whose patent protection has expired. This allows patients to receive a more cost-effective alternative treatment. Overall, ANI Pharmaceuticals has a strong focus on manufacturing cost-effective and high-quality medications for patients and healthcare facilities. The company has an excellent product range and is well positioned to offer innovative and highly effective drugs for the treatment of diseases in the future. ANI Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding ANI Pharmaceuticals's P/S Ratio

ANI Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing ANI Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating ANI Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in ANI Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about ANI Pharmaceuticals stock

What is the price-to-earnings ratio of ANI Pharmaceuticals?

The price-earnings ratio of ANI Pharmaceuticals is currently 1.94.

How has the price-earnings ratio of ANI Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of ANI Pharmaceuticals has increased by 12.14% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of ANI Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of ANI Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of ANI Pharmaceuticals affect the company?

An increase in the price-earnings ratio of ANI Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of ANI Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of ANI Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of ANI Pharmaceuticals?

Some factors that influence the price-earnings ratio of ANI Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does ANI Pharmaceuticals pay?

Over the past 12 months, ANI Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ANI Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of ANI Pharmaceuticals?

The current dividend yield of ANI Pharmaceuticals is .

When does ANI Pharmaceuticals pay dividends?

ANI Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ANI Pharmaceuticals?

ANI Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of ANI Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ANI Pharmaceuticals located?

ANI Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von ANI Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ANI Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did ANI Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of ANI Pharmaceuticals in the year 2023?

In the year 2023, ANI Pharmaceuticals distributed 0 USD as dividends.

In which currency does ANI Pharmaceuticals pay out the dividend?

The dividends of ANI Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ANI Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ANI Pharmaceuticals

Our stock analysis for ANI Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ANI Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.